News | February 24, 2009

BrachySciences Now Distributes All Three Isotopes for Low Dose Rate Prostate Brachytherapy

February 24, 2009 - BrachySciences, a provider of medical devices for the treatment of early stage prostate cancer, has signed a distribution agreement with IsoRay Inc. to distribute manufacturer of Proxcelan, making BrachySciences the only provider of all three radioactive isotopes used in low dose rate (LDR) prostate brachytherapy.

IsoRay’s Cesium-131 is the only radioactive source available for brachytherapy. BrachySciences has added Cesium-131 source to its distribution portfolio of Advantage Iodine-125 and the TheraSeed Palladium-103 device.

With access to all three isotopes and a diverse brachytherapy product portfolio capable of satisfying any pre-planned or real-time implant technique, BrachySciences has the ability to function as a solitary vendor and complete service provider to hospitals and clinics with LDR implant programs.

For more information: brachysciences.com

Related Content

Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
Prostate Brachytherapy Shows Low Incidence of Short-Term Complications
News | Brachytherapy Systems | October 31, 2018
A new analysis of nearly 600 men receiving brachytherapy for prostate cancer shows overall procedure-related...
News | Brachytherapy Systems, Women's Healthcare | October 25, 2018
iCAD Inc. announced new clinical research demonstrating positive outcomes supporting the use of the Xoft Axxent...
Xoft Electronic Brachytherapy System Effective Long-Term for Early-Stage Breast Cancer
News | Brachytherapy Systems, Women's Healthcare | October 02, 2018
Breast cancer recurrence rates for patients treated with the Xoft Axxent Electronic Brachytherapy (eBx) System that...
News | Radiation Dose Management | September 24, 2018
AngioDynamics Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company...
Varian Showcases Advanced Cancer Care Solutions at AAPM 2018
News | Radiation Therapy | July 27, 2018
Varian announced it will be showcasing its advanced cancer care solutions, including a new version of the Eclipse...
Florida Hospital First in State to Adopt NeuroLogica's BodyTom Elite CT
News | Computed Tomography (CT) | June 14, 2018
June 14, 2018 — NeuroLogica, a subsidiary of Samsung Electronics Co.
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.